indomethacin has been researched along with Sarcoma 180 in 4 studies
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.
Sarcoma 180: An experimental sarcoma of mice.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Recombinant human TGF alpha-induced bone resorption was completely inhibited by indomethacin." | 5.29 | Ascites sarcoma 180, a tumor associated with hypercalcemia, secretes potent bone-resorbing factors including transforming growth factor alpha, interleukin-1 alpha and interleukin-6. ( Suzuki, K; Yamada, S, 1994) |
| "The mechanism of the enhanced vascular permeability and retention (EPR) effect seen in solid tumors was investigated with sarcoma 180 (S-180) in mice by using the bradykinin receptor antagonist D-Arg-[Hyp3,Thi5,D-Tic7,Oic8]bradykinin] (HOE 140), the nitric oxide (NO) scavenger 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide (PTIO), and the cyclooxygenase (prostaglandin synthase) inhibitor indomethacin." | 3.70 | Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. ( Akaike, T; Maeda, H; Wu, J, 1998) |
| "Recombinant human TGF alpha-induced bone resorption was completely inhibited by indomethacin." | 1.29 | Ascites sarcoma 180, a tumor associated with hypercalcemia, secretes potent bone-resorbing factors including transforming growth factor alpha, interleukin-1 alpha and interleukin-6. ( Suzuki, K; Yamada, S, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jones, GR | 1 |
| Suzuki, K | 1 |
| Yamada, S | 1 |
| Wu, J | 1 |
| Akaike, T | 1 |
| Maeda, H | 1 |
| Ohshika, Y | 1 |
| Umesaki, N | 1 |
| Sugawa, T | 1 |
4 other studies available for indomethacin and Sarcoma 180
| Article | Year |
|---|---|
Prevention of drug-induced upset to energy production in the S180 sarcoma by inhibition of prostaglandin synthetase [proceedings].
Topics: Adenine Nucleotides; Animals; Cyclooxygenase Inhibitors; Endotoxins; Energy Metabolism; Hydralazine; | 1980 |
Ascites sarcoma 180, a tumor associated with hypercalcemia, secretes potent bone-resorbing factors including transforming growth factor alpha, interleukin-1 alpha and interleukin-6.
Topics: Animals; Antibodies; Blotting, Northern; Bone Resorption; Culture Media, Conditioned; Cyclic AMP; Di | 1994 |
Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger.
Topics: Animals; Arginine; Ascites; Bradykinin; Bradykinin Receptor Antagonists; Capillary Permeability; Cyc | 1998 |
Immunomodulating capacity of the monocyte-macrophage system in patients with uterine cervical cancer.
Topics: Adjuvants, Immunologic; Animals; Carcinoma in Situ; Female; Humans; Indomethacin; Interleukin-1; Mac | 1988 |